# A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT07502027** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Huazhong University of Science and Technology** · enrollment: 55 (estimated)

## Conditions studied

- Gastric Cancer (Diagnosis)
- Gastric Cancer (GC)
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab (QL1706)

## Key facts

- **NCT ID:** NCT07502027
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502027, "A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07502027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*